JPH04501719A - ポリペプチド - Google Patents

ポリペプチド

Info

Publication number
JPH04501719A
JPH04501719A JP1511698A JP51169889A JPH04501719A JP H04501719 A JPH04501719 A JP H04501719A JP 1511698 A JP1511698 A JP 1511698A JP 51169889 A JP51169889 A JP 51169889A JP H04501719 A JPH04501719 A JP H04501719A
Authority
JP
Japan
Prior art keywords
item
items
cells
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1511698A
Other languages
English (en)
Japanese (ja)
Inventor
テイラー―パパデイミトリオウ，ジヨイス
ジエンドラー，サンドラ
バーチエル，ジヨイ
Original Assignee
インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888826362A external-priority patent/GB8826362D0/en
Priority claimed from GB898907660A external-priority patent/GB8907660D0/en
Application filed by インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド filed Critical インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド
Publication of JPH04501719A publication Critical patent/JPH04501719A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP1511698A 1988-11-10 1989-11-10 ポリペプチド Pending JPH04501719A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8826362.9 1988-11-10
GB888826362A GB8826362D0 (en) 1988-11-10 1988-11-10 Polypeptide
GB898907660A GB8907660D0 (en) 1989-04-05 1989-04-05 Polypeptide
GB8907660.8 1989-04-05

Publications (1)

Publication Number Publication Date
JPH04501719A true JPH04501719A (ja) 1992-03-26

Family

ID=26294608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1511698A Pending JPH04501719A (ja) 1988-11-10 1989-11-10 ポリペプチド

Country Status (3)

Country Link
EP (1) EP0442926A1 (fr)
JP (1) JPH04501719A (fr)
WO (1) WO1990005142A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339204C (fr) * 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Polypeptides, anticorps et sondes a noyau de mucine
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
DE69329643T2 (de) * 1992-04-13 2001-03-01 Dana Farber Cancer Inst Inc Gegen karzinom-assoziierte antigene gerichtete antikörper
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU2247095A (en) * 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
AU2540897A (en) * 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
GB9717946D0 (en) * 1997-08-22 1997-10-29 Imp Cancer Res Tech Novel chemical entity
DK1027063T3 (da) 1997-09-29 2009-06-02 Macfarlane Burnet Inst For Med Mannosereceptorbærende cellelinje og antigensammensætning
EP1369428A1 (fr) * 1997-10-31 2003-12-10 Biomira Inc. Dérivés de Muc-1 et leur utilisation dans le traitement d'immunosupression induite par le MUC-1 Mucin associé au cancer
JP2002526380A (ja) * 1997-10-31 2002-08-20 バイオミラ，インコーポレイテッド 癌関連ｍｕｃ−１ムチン誘発免疫抑制の治療におけるｍｕｃ−１誘導体とその使用法
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE19758400A1 (de) * 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010093784A2 (fr) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
EP2673289B1 (fr) 2011-02-10 2023-05-03 The University of North Carolina At Chapel Hill Vecteurs viraux à profil de transduction modifiée et procédés pour les préparer et les utiliser
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
IL298049B2 (en) 2013-03-15 2023-10-01 Univ North Carolina Chapel Hill Methods and compounds for ligation of paired AAV glycan vectors
EP2970966A4 (fr) 2013-03-15 2016-10-26 Univ North Carolina Répétitions terminales inversées de synthèse du virus adéno-associé
RU2727015C2 (ru) 2014-11-21 2020-07-17 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Векторы aav, нацеленные на центральную нервную систему
CA2972807C (fr) 2015-01-14 2024-01-16 The University Of North Carolina At Chapel Hill Procedes et compositions destines au transfert de genes cible
KR102554850B1 (ko) 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
EP3258961A4 (fr) 2015-02-20 2018-08-22 Board of Regents, The University of Texas System Méthodes et compositions permettant d'utiliser la chlamydia atténuée en tant que vaccin et vecteur
SG10202107733QA (en) 2015-09-28 2021-09-29 Univ North Carolina Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2017087763A1 (fr) 2015-11-18 2017-05-26 Orbis Health Solutions Llc Système de vecteur viral alpha t7
CN117801075A (zh) 2017-03-15 2024-04-02 北卡罗来纳-查佩尔山大学 多倍体腺相关病毒载体及其制备和使用方法
KR20210007963A (ko) 2018-04-03 2021-01-20 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
EP3773743A1 (fr) 2018-04-03 2021-02-17 Stridebio, Inc. Vecteurs de virus permettant de cibler des tissus ophtalmiques
KR20210006357A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
CA3104113A1 (fr) 2018-06-22 2019-12-26 Asklepios Biopharmaceutical, Inc. Vecteurs pour l'administration de genes qui persistent dans les cellules
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
EP4169535A1 (fr) 2019-04-26 2023-04-26 The University of North Carolina at Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
US20230392163A1 (en) 2019-10-17 2023-12-07 Ginkgo Bioworks Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
EP4010356A4 (fr) 2020-10-28 2023-01-04 The University of North Carolina at Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
WO2022093769A1 (fr) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
WO2023150687A1 (fr) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Vecteurs viraux adéno-associés recombinants et méthodes d'utilisation associées

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339204C (fr) * 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Polypeptides, anticorps et sondes a noyau de mucine

Also Published As

Publication number Publication date
EP0442926A1 (fr) 1991-08-28
WO1990005142A1 (fr) 1990-05-17

Similar Documents

Publication Publication Date Title
JPH04501719A (ja) ポリペプチド
US11447536B2 (en) High avidity antigen recognizing constructs
US6344203B1 (en) Mimicking peptides in cancer therapy
ES2240981T3 (es) Citocina denominada lerk-7.
ES2652017T3 (es) Métodos y composiciones farmacéuticas para el engaño inmunitario, particularmente útiles en el tratamiento de cáncer
US9452204B2 (en) Chimeric peptides comprising HER-2 B-cell epitopes and Tcell helper epitopes
JPH09501159A (ja) 合成多重縦列反復ムチンおよびムチン様ペプチド、並びにそれらの利用
US7268207B2 (en) Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
EA030777B1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
JPH09505723A (ja) ４３ｋｄヒトガン抗原からの免疫反応性ペプチド配列
US7358087B2 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
Insug et al. Role of SA–Lea and E-selectin in metastasis assessed with peptide antagonist
WO2011091716A1 (fr) Variante du récepteur du facteur de croissance épidermique
Liang et al. Antibody binding to a peptide but not the whole protein by recognition of the C-terminal carboxy group
CN1082053A (zh) 合成多肽
EP1167387A1 (fr) Anticorps anti-SEMP1, procédé pour leur production, et leurs utilisations
US20240182577A1 (en) Anti-pd-1 signal peptide antibody and use thereof
JP2005513040A (ja) Ｔｌｐペプチドを含む融合タンパク質
US20050063970A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
CN103539840B (zh) 表皮生长因子受体模拟表位肽及其应用
Xing et al. Peptide epitopes in breast cancer mucins
JP4037451B2 (ja) 大腸細胞および大腸癌細胞関連核酸分子、タンパク質およびペプチド
CN117858897A (zh) 抗pd-1信号肽抗体及其应用
CN1668640A (zh) 肿瘤标志物及其用途
CN1622955A (zh) 肿瘤标志物及其用途